FILING ANALYSIS · MONDAY, NOVEMBER 16

Unicycive Therapeutics, Inc. UNCY — 8-K: Results of Operations and Financial Condition

neutral

The FDA's acceptance of Unicycive Therapeutics' New Drug Application (NDA) resubmission for oxylanthanum carbonate (OLC) with a PDUFA target action date of March 25, 2027, is a positive development, and the company's cash runway beyond 2027 provides financial stability. However, this news is likely already priced in, given the previous announcement of the NDA acceptance in October.

The filing

8-K - Unicycive Therapeutics, Inc. (0001766140) (Filer)

Read the filing on SEC EDGAR →

How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.

Get filings like this every market day

The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.

Subscribe free →
All analyses · Earnings today · Latest brief · Track record
© 2026 Dutchcode B.V. · Built by
Blinkof.ai verified — grade A+